W. Rabitsch et al., Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies, BONE MAR TR, 22, 1998, pp. S49-S52
Citations number
5
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Between 1995 and 1997 twenty two patients with different hematological dise
ases ( CML n=10, AML n=6, ALL n=1, NHL n=3, SAA n=1,solid tumor n=1) and a
median age of 37 (range, 20 to 55) years received unmanipulated peripheral
blood stem cell (PBSC) transplants from HLA-identical sibling donors at our
institution. Myeloablative chemotherapy consisted of cyclophosphamide (CY)
and total body irradiation in 11, and chemotherapy alone in 11 patients. F
or graft-versus host-disease (GVHD) prophylaxis all patients were given cyc
losporine A and methotrexate according to the Seattle protocol. PBSC were m
obilized by granulocyte colony-stimulating factor (G-CSF) given at 10 mu g/
kg body weight (b.w.)/day for four days. Harvest of PBSC was started on day
5 and continued on day 6 if necessary. A median of 1 leukapheresis (range,
1 to 2) was performed and a median of 5.7 x 10(6).